Home > Resources > Whitepapers > Pharma R&D Annual Review 2019 Supplement

Pharma R&D Annual Review 2019 Supplement

March 21, 2019

Following on from our review of trends in the current pharmaceutical R&D pipeline, published in March 2019 this supplement takes a look at the industry’s success stories of 2018 – the drugs which were launched on to the market for the first time during the year. Our survey focuses exclusively on new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use. This will include vaccines with novel antigenic components. As such, this list represents a subset of all the first launches which Pharmaprojects reported during 2018, excluding the 67 new drug launches with reformulated or non-NAS moieties, or biosimilars. So, to continue our sports theme this year, we’ll be looking at the drugs which successfully crossed the finishing line, hit the bullseye, and lifted the trophy, to become part of pharma’s elite 2018 team. In pharma as in sport, it’s all about winning. Pharma

Spotlight

Functional Genetics

Functional Genetics, Inc. (FGI) is a development-stage biotechnology company that uses innovative science to develop new therapeutics for infectious disease. Our novel antiviral products address widespread and intractable diseases that have persistently inflicted considerable suffering and death.

OTHER WHITEPAPERS

Shifting to an Audience-Focused Product Marketing Strategy

whitePaper | February 24, 2023

The WBR Insights research team surveyed 100 leaders from pharmaceutical companies to generate the results featured in this report. The respondents occupy roles in marketing, sales, commercial strategy, and product development.

Characterization of Protein Aggregates and Other Particles in Biopharmaceuticals

whitePaper | July 8, 2022

Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

Strengthening Engagement and Influence with Key Decision Makers

whitePaper | January 5, 2023

This report follows up on the jointly hosted Pharmaforce and elandas webinar which took place on July, 12, 2016, featuring contributions from participating industry leaders who formed the expert panel, as well as the live contributions of the audience of healthcare sales and marketing professionals.

AI Powered Business Intelligence for Life Science Leaders: Save Time, Drive Adoption and Scale Faster

whitePaper | February 20, 2023

Once the industry has normalized after a turbulent 2020, life sciences leaders can still count on continued change. The future will be challenging at best without the support of next-gen BI as life sciences navigate their businesses through new or growing competition, economic recovery, regulatory and political pressures, barriers to market access, and an increased demand for personalized medicine.

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of any company. For those in pharmaceutical contract research, development, or manufacturing.

Shifting to an Audience-Focused Product Marketing Strategy

whitePaper | February 24, 2023

Characterization of Protein Aggregates and Other Particles in Biopharmaceuticals

whitePaper | July 8, 2022

Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

Strengthening Engagement and Influence with Key Decision Makers

whitePaper | January 5, 2023

AI Powered Business Intelligence for Life Science Leaders: Save Time, Drive Adoption and Scale Faster

whitePaper | February 20, 2023

Once the industry has normalized after a turbulent 2020,
life sciences leaders can still count on continued change.
The future will be challenging at best without the support
of next-gen BI as life sciences navigate their businesses
through new or growing competition, economic recovery,
regulatory and political pressures, barriers to market access,
and an increased demand for personalized medicine.

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of
any company. For those in pharmaceutical contract research, development, or manufacturing.

More Whitepapers

Pharma R&D Annual Review 2019 Supplement

Spotlight

Functional Genetics

OTHER WHITEPAPERS

Shifting to an Audience-Focused Product Marketing Strategy

Characterization of Protein Aggregates and Other Particles in Biopharmaceuticals

Drug Solubility and the Need for Speed

Strengthening Engagement and Influence with Key Decision Makers

AI Powered Business Intelligence for Life Science Leaders: Save Time, Drive Adoption and Scale Faster

Alcami Grows Contract Manufacturing and Laboratory Business 20%

Shifting to an Audience-Focused Product Marketing Strategy

Characterization of Protein Aggregates and Other Particles in Biopharmaceuticals

Drug Solubility and the Need for Speed

Strengthening Engagement and Influence with Key Decision Makers

AI Powered Business Intelligence for Life Science Leaders: Save Time, Drive Adoption and Scale Faster

Alcami Grows Contract Manufacturing and Laboratory Business 20%

Spotlight

Functional Genetics

Events